Advertisement
Screener

Surrozen, Inc./DE (SRZN) Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

2.8 / 5 stars · 68/120 Roast Me

Surrozen, Inc./DE Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

Surrozen, Inc./DE (SRZN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $692.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-23.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-23

  • 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $692.00K.
  • 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $312.00K.
  • 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $322.00K.
  • 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $201.00K.
Period endDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
2025-12-31$692.00K
10-K · filed 2026-03-23
2024-12-31$312.00K
10-K · filed 2026-03-23
2023-12-31$322.00K
10-K · filed 2025-03-31
2022-12-31$201.00K
10-K · filed 2024-04-10
2021-12-31$129.00K
10-K · filed 2023-03-31
2020-12-31$2.00K
10-K · filed 2022-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zura Bio Ltd (ZURA)$0.398B-6.56
AGENUS INC (AGEN)United States$0.383B1.41
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Eikon Therapeutics, Inc. (EIKN)United States$0.446B